Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. / Ahrén, Bo; Holst, Jens Juul; Mari, Andrea.

In: Diabetes Care. Supplement, Vol. 26, No. 10, 10.2003, p. 2860-4.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ahrén, B, Holst, JJ & Mari, A 2003, 'Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans', Diabetes Care. Supplement, vol. 26, no. 10, pp. 2860-4.

APA

Ahrén, B., Holst, J. J., & Mari, A. (2003). Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care. Supplement, 26(10), 2860-4.

Vancouver

Ahrén B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care. Supplement. 2003 Oct;26(10):2860-4.

Author

Ahrén, Bo ; Holst, Jens Juul ; Mari, Andrea. / Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. In: Diabetes Care. Supplement. 2003 ; Vol. 26, No. 10. pp. 2860-4.

Bibtex

@article{656c152bb4574a7691c940bd5c873817,
title = "Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans",
abstract = "OBJECTIVE: Glucagon-like peptide 1 (GLP-1) is an incretin that augments insulin secretion after meal intake and is developed for treatment of type 2 diabetes. As a novel therapeutic agent, characteristics of its beta-cell effects are important to establish. Previously, beta-cell effects of GLP-1 have been characterized in humans during graded intravenous infusions of glucose, whereas its effects after more physiological stimuli, like meal intake, are not known.RESEARCH DESIGN AND METHODS: Eight women (aged 69 years, fasting glucose 3.7-10.3 mmol/l, BMI 22.4-43.9 kg/m(2)) who had fasted overnight were served a breakfast (450 kcal) with intravenous infusion of saline or synthetic GLP-1 (0.75 pmol x kg(-1) x min(-1)), and beta-cell function was evaluated by estimating the relationship between glucose concentration and insulin secretion (calculated by deconvolution of C-peptide data).RESULTS: -GLP-1 markedly augmented insulin secretion, despite lower glucose. Total insulin secretion was 29.7 +/- 4.2 nmol/m(2) with GLP-1 versus 21.0 +/- 1.6 nmol/m(2) with saline (P = 0.048). GLP-1 increased the dose-response relationship between glucose concentration and insulin secretion (70 +/- 26 with GLP-1 versus 38 +/- 16 pmol insulin. min(-1 x m(2). mmol(-1) glucose. l without, P = 0.037) and augmented the potentiation factor that modulates the dose response (2.71 +/- 0.42 with GLP-1 versus 0.97 +/- 0.17 without, P = 0.005). The potentiation factor correlated to GLP-1 concentration (r = 0.53, P < 0.001); a 10-fold increase in GLP-1 levels produced a twofold increase in the potentiation factor. These effects of GLP-1 did not correlate with fasting glucose levels or BMI.CONCLUSIONS: Administration of GLP-1 along with ingestion of a meal augments insulin secretion in humans by a dose-dependent potentiation of the dose-response relationship between plasma glucose and insulin secretion.",
keywords = "Aged, Blood Glucose, C-Peptide, Eating, Female, Glucagon, Glucagon-Like Peptide 1, Humans, Insulin, Islets of Langerhans, Peptide Fragments, Postprandial Period, Protein Precursors",
author = "Bo Ahr{\'e}n and Holst, {Jens Juul} and Andrea Mari",
year = "2003",
month = oct,
language = "English",
volume = "26",
pages = "2860--4",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association",
number = "10",

}

RIS

TY - JOUR

T1 - Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans

AU - Ahrén, Bo

AU - Holst, Jens Juul

AU - Mari, Andrea

PY - 2003/10

Y1 - 2003/10

N2 - OBJECTIVE: Glucagon-like peptide 1 (GLP-1) is an incretin that augments insulin secretion after meal intake and is developed for treatment of type 2 diabetes. As a novel therapeutic agent, characteristics of its beta-cell effects are important to establish. Previously, beta-cell effects of GLP-1 have been characterized in humans during graded intravenous infusions of glucose, whereas its effects after more physiological stimuli, like meal intake, are not known.RESEARCH DESIGN AND METHODS: Eight women (aged 69 years, fasting glucose 3.7-10.3 mmol/l, BMI 22.4-43.9 kg/m(2)) who had fasted overnight were served a breakfast (450 kcal) with intravenous infusion of saline or synthetic GLP-1 (0.75 pmol x kg(-1) x min(-1)), and beta-cell function was evaluated by estimating the relationship between glucose concentration and insulin secretion (calculated by deconvolution of C-peptide data).RESULTS: -GLP-1 markedly augmented insulin secretion, despite lower glucose. Total insulin secretion was 29.7 +/- 4.2 nmol/m(2) with GLP-1 versus 21.0 +/- 1.6 nmol/m(2) with saline (P = 0.048). GLP-1 increased the dose-response relationship between glucose concentration and insulin secretion (70 +/- 26 with GLP-1 versus 38 +/- 16 pmol insulin. min(-1 x m(2). mmol(-1) glucose. l without, P = 0.037) and augmented the potentiation factor that modulates the dose response (2.71 +/- 0.42 with GLP-1 versus 0.97 +/- 0.17 without, P = 0.005). The potentiation factor correlated to GLP-1 concentration (r = 0.53, P < 0.001); a 10-fold increase in GLP-1 levels produced a twofold increase in the potentiation factor. These effects of GLP-1 did not correlate with fasting glucose levels or BMI.CONCLUSIONS: Administration of GLP-1 along with ingestion of a meal augments insulin secretion in humans by a dose-dependent potentiation of the dose-response relationship between plasma glucose and insulin secretion.

AB - OBJECTIVE: Glucagon-like peptide 1 (GLP-1) is an incretin that augments insulin secretion after meal intake and is developed for treatment of type 2 diabetes. As a novel therapeutic agent, characteristics of its beta-cell effects are important to establish. Previously, beta-cell effects of GLP-1 have been characterized in humans during graded intravenous infusions of glucose, whereas its effects after more physiological stimuli, like meal intake, are not known.RESEARCH DESIGN AND METHODS: Eight women (aged 69 years, fasting glucose 3.7-10.3 mmol/l, BMI 22.4-43.9 kg/m(2)) who had fasted overnight were served a breakfast (450 kcal) with intravenous infusion of saline or synthetic GLP-1 (0.75 pmol x kg(-1) x min(-1)), and beta-cell function was evaluated by estimating the relationship between glucose concentration and insulin secretion (calculated by deconvolution of C-peptide data).RESULTS: -GLP-1 markedly augmented insulin secretion, despite lower glucose. Total insulin secretion was 29.7 +/- 4.2 nmol/m(2) with GLP-1 versus 21.0 +/- 1.6 nmol/m(2) with saline (P = 0.048). GLP-1 increased the dose-response relationship between glucose concentration and insulin secretion (70 +/- 26 with GLP-1 versus 38 +/- 16 pmol insulin. min(-1 x m(2). mmol(-1) glucose. l without, P = 0.037) and augmented the potentiation factor that modulates the dose response (2.71 +/- 0.42 with GLP-1 versus 0.97 +/- 0.17 without, P = 0.005). The potentiation factor correlated to GLP-1 concentration (r = 0.53, P < 0.001); a 10-fold increase in GLP-1 levels produced a twofold increase in the potentiation factor. These effects of GLP-1 did not correlate with fasting glucose levels or BMI.CONCLUSIONS: Administration of GLP-1 along with ingestion of a meal augments insulin secretion in humans by a dose-dependent potentiation of the dose-response relationship between plasma glucose and insulin secretion.

KW - Aged

KW - Blood Glucose

KW - C-Peptide

KW - Eating

KW - Female

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Insulin

KW - Islets of Langerhans

KW - Peptide Fragments

KW - Postprandial Period

KW - Protein Precursors

M3 - Journal article

C2 - 14514592

VL - 26

SP - 2860

EP - 2864

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -

ID: 132055876